Mon. 13 May 2024, 6:10am ET
Benzinga
News, Health Care, General
- First 14 participants with at least six months of follow up continue to demonstrate sustained improvements in blood glucose and weight with reduction in T2D medication utilization after a single Revita treatment.
- No device- or procedure-related serious adverse events have been observed to date in any registry participant.